查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800829

2025 年至 2033 年葡萄膜炎治疗市场报告（依治疗类型、疾病类型、病因、配销通路和地区）

Uveitis Treatment Market Report by Treatment Type, Disease Type, Cause, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球葡萄膜炎治疗市场规模达18亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到27亿美元，2025-2033年期间的复合年增长率（CAGR）为4.44%。受以下因素推动，该市场正在经历显着增长：葡萄膜炎发病率的上升；各种生物製剂和免疫抑制疗法的持续研发活动，旨在丰富治疗方案；对提高认知度和早期诊断的重视；政府的优惠政策以及医疗报销政策。

葡萄膜炎治疗市场趋势：

自体免疫疾病盛行率不断上升

全球自体免疫疾病的发生率不断上升，刺激了对葡萄膜炎治疗的需求。根据美国国立卫生研究院 (NIH) 报告，估计有 2,350 万美国人患有自体免疫疾病，这些疾病包括类风湿性关节炎、发炎性肠道疾病、狼疮等，并最终发展为葡萄膜炎。值得注意的是，这种盛行率证明了对针对自体免疫疾病的有效葡萄膜炎疗法的需求很高，并刺激了市场需求。因此，随着这些疾病在世界各地的蔓延，治疗的目标是控制葡萄膜炎及其相关症状，并针对导致疾病的自身免疫过程，从而改善患者的生活。

生物製剂和免疫疗法的进展

生物製剂和免疫调节疗法透过调节免疫介导过程，彻底改变了葡萄膜炎的治疗。美国国立卫生研究院 (NIH) 已批准多种用于治疗自体免疫疾病（例如葡萄膜炎）的生物製剂，这标誌着人们正转向使用经济高效的生物製剂。此类疗法的优点在于，与皮质类固醇等其他疗法相比，其副作用对身体其他器官的影响机率更低，从而提高了患者对推荐治疗方案的依从性。因此，生物技术和免疫学市场的持续发展促进了生物製剂和免疫调节剂产品的开发，从而扩大了全球市场中葡萄膜炎治疗的机会。

医疗支出和研究经费不断增加

政府在医疗体系方面的支出增加、发展策略以及医疗保健领域的进步，正在推动葡萄膜炎治疗市场的价值成长。在美国，美国国立卫生研究院 (NIH) 为研究葡萄膜炎和其他自体免疫疾病提供大量资金，这项研究是大学、製药业和医院之间多部门、多方合作的成果。这些资金支持进一步推动了葡萄膜炎新疗法的进展，因为它推动了新药、生物製剂和治疗方法的发展。此外，政府资助的研究经费和临床试验提供了必要的框架和资源，以支持探索新的治疗方法并验证治疗的有效性。这些动态使得葡萄膜炎治疗市场高度依赖研究，因为它致力于将新发现转化为临床有用的产品和服务，以满足现有需求并提升全球患者体验。

葡萄膜炎治疗市场细分：

依治疗类型分类：

  • 皮质类固醇
  • 免疫抑制剂
  • 单株抗体
  • 睫状肌麻痹剂
  • 抗生素
  • 抗病毒药物
  • 抗真菌
  • 止痛药

皮质类固醇占大部分市场份额

根据葡萄膜炎治疗市场预测，皮质类固醇在葡萄膜炎治疗市场中占据主导地位，因为它们有助于减轻发炎并维持患者视力。美国国立卫生研究院 (NIH) 报告称，皮质类固醇是治疗葡萄膜炎的主要药物，因为它们能够快速控制发炎以及不同类型葡萄膜炎（前葡萄膜炎、后葡萄膜炎和全葡萄膜炎）的症状。这些药物的主要适应症是降低身体抵抗眼部感染的能力并减轻炎症，从而快速有效地缓解症状并改善患者的健康状况。皮质类固醇可以透过眼药水、注射和口服药片给药，这取决于病情严重程度和患者的具体情况。由于皮质类固醇可能存在副作用，包括长期使用会导致眼压升高和术后白内障形成，因此它们仍然比其他竞争对手更受欢迎，而中等疗效的局部非类固醇抗发炎药物 (NSAID) 儘管在眼科实践中经常使用，但在葡萄膜炎治疗中却不那么受欢迎。

依疾病类型分类：

  • 前葡萄膜炎
  • 后葡萄膜炎
  • 中间葡萄膜炎
  • 全葡萄膜炎

前葡萄膜炎占业界最大份额

前葡萄膜炎因其发病率较高且需要特殊治疗，在葡萄膜炎治疗领域占据领先地位。美国国立卫生研究院 (NIH) 将前葡萄膜炎归类为最常见的葡萄膜炎类型，占美国已报告所有葡萄膜炎病例的 50-60%。前葡萄膜炎是由眼球前部结构（称为葡萄膜）的发炎引起的，与自体免疫疾病、感染或身体损伤有关。因此，这种模式意味着前葡萄膜炎的治疗需要不同的管理策略，例如局部使用皮质类固醇和扩瞳剂，这些药物在诊所、眼科和零售店均有常规使用，从而创造了良好的市场前景。

分手原因：

  • 传染性
  • 非传染性

非传染性药物占主要市场份额

非感染性葡萄膜炎治疗市场收入主要来自非感染性葡萄膜炎，因为这种疾病比感染性葡萄膜炎更常见，并且可以透过改进的实证个别化治疗来应对自体免疫和发炎过程。根据美国国立卫生研究院 (NIH) 的数据，非感染性葡萄膜炎约占美国所有葡萄膜炎病例的 80% 至 90%。这种类型的葡萄膜炎与自体免疫疾病（例如类风湿性关节炎、发炎性肠道疾病、狼疮）以及对生物製剂和免疫调节剂的需求更为相关。世界各地的研究人员观察到，自体免疫疾病的病例正在持续增加，这增强了非感染性葡萄膜炎治疗的市场地位。现代製药业致力于开发合适的个人化抗葡萄膜炎製剂，以更有效地针对非感染性葡萄膜炎的免疫致病背景，同时最大程度地减少全身给药的副作用，从而为葡萄膜炎治疗市场创造了良好的前景。

依配销通路分类：

  • 医院药房
  • 零售药局
  • 网路药局
  • 其他的

零售药局在市场上占据明显主导地位

零售药局在葡萄膜炎治疗市场占有最大份额，主要是因为它们易于取得且便捷，尤其是对患者而言，而且它们也参与药品调配。美国社区药剂师协会 (NCPA) 报告称，美国零售药局调配了约 72% 的处方，这凸显了药剂师在药物调配中的核心地位。这份葡萄膜炎治疗市场概览显示，确诊患有葡萄膜炎的患者可以从零售药局以更快的速度便捷地获得处方药，例如皮质类固醇、免疫抑制剂和生物製剂。此外，零售药局也提供病患咨询、药物和健康保险资讯及管理，从而提高了病患的满意度和治疗效果。利害关係人透过它们与医疗系统和电子健康记录进行交互，从而为葡萄膜炎患者提供持续的护理。由于零售药局服务日益多样化，以及对患者和消费者的关注日益加深，它们在满足市场对葡萄膜炎药物日益增长的需求和主导药品分销方面做出了巨大贡献。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美引领市场，占据葡萄膜炎治疗市场最大份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）、亚太地区（中国、日本、印度、韩国、澳洲、印尼等）、欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）、拉丁美洲（巴西、墨西哥等）以及中东和非洲。报告指出，北美是葡萄膜炎治疗最大的区域市场。

根据葡萄膜炎治疗市场报告，北美凭藉其发达先进的医疗保健产业、对新型治疗方案的接受度以及对研发的直接投入，占据最大的市场份额。根据美国国立卫生研究院 (NIH) 报告，仅在美国，自体免疫疾病研究的预算就已相当可观，并且为进行大量临床试验以及各製药实体、研究机构和护理人员之间的合作提供了有利的环境。此类策略性投资使北美国家能够在生物製剂、免疫调节剂和其他治疗葡萄膜炎的方法的开发和商业化方面占据领先地位。此外，由于自体免疫疾病（后来发展为葡萄膜炎）的发生率较高，北美地区需要高效的葡萄膜炎治疗和管理，从而占据全球葡萄膜炎市场的领导地位。

（请注意，这只是关键参与者的部分列表，完整列表在报告中提供。）

  • 专注于葡萄膜炎治疗药物研发的製药公司和研究机构正透过临床试验来应对葡萄膜炎疾病发展过程中的各种挑战。艾伯维、诺华和艾尔建等市场领导者致力于研发针对葡萄膜炎发展特定免疫过程的新药。例如，艾伯维的研究策略包括近期的合作和临床试验，探索生物製剂在自体免疫性葡萄膜炎中的应用，体现了其对精准医疗的重视。许多此类活动由政府和研究机构资助，旨在促进产学合作，在葡萄膜炎治疗模式转变的背景下推进治疗进展并改善患者护理，从而推动葡萄膜炎治疗行业的发展。

本报告回答的关键问题

  • 2024 年全球葡萄膜炎治疗市场规模是多少
  • 2025-2033年全球葡萄膜炎治疗市场的预期成长率是多少
  • COVID-19 对全球葡萄膜炎治疗市场有何影响
  • 推动全球葡萄膜炎治疗市场的关键因素有哪些
  • 根据治疗类型，全球葡萄膜炎治疗市场如何划分
  • 根据疾病类型，全球葡萄膜炎治疗市场如何划分
  • 全球葡萄膜炎治疗市场按病因划分如何
  • 根据配销通路，全球葡萄膜炎治疗市场如何分布
  • 全球葡萄膜炎治疗市场的主要区域有哪些
  • 10. 全球葡萄膜炎治疗市场的主要参与者/公司有哪些？

本报告回答的关键问题

  • 2024年全球葡萄膜炎治疗市场规模？ 2025-2033年全球葡萄膜炎治疗市场的预期成长率是多少？
  • COVID-19 对全球葡萄膜炎治疗市场有何影响？
  • 推动全球葡萄膜炎治疗市场发展的关键因素有哪些？
  • 根据治疗类型，全球葡萄膜炎治疗市场如何分布？
  • 根据疾病类型，全球葡萄膜炎治疗市场是如何分布的？
  • 全球葡萄膜炎治疗市场依病因分为哪些类型？
  • 根据配销通路，全球葡萄膜炎治疗市场如何分布？
  • 全球葡萄膜炎治疗市场的主要地区有哪些？
  • 全球葡萄膜炎治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球葡萄膜炎治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依治疗类型

  • 皮质类固醇
  • 免疫抑制剂
  • 单株抗体
  • 睫状肌麻痹剂
  • 抗生素
  • 抗病毒药物
  • 抗真菌
  • 止痛药

第七章：市场区隔：依疾病类型

  • 前葡萄膜炎
  • 后葡萄膜炎
  • 中间葡萄膜炎
  • 全葡萄膜炎

第八章：市场分化：依原因

  • 传染性
  • 非传染性

第九章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局
  • 其他的

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Alimera Sciences Inc.
    • Bausch & Lomb Incorporated (Bausch Health)
    • Enzo Biochem Inc.
    • Eyegate Pharmaceuticals Inc.
    • Eyepoint pharmaceuticals Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • Santen Pharmaceutical Co. Ltd.
Product Code: SR112025A2759

The global uveitis treatment market size reached USD 1.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.44% during 2025-2033. The market is experiencing significant growth driven by the rising incidence of uveitis, ongoing research and development activities in various biologics and immunosuppressive treatments to diversify treatment possibilities, heightening emphasis on increasing awareness and early diagnosis, favorable government policies, and healthcare reimbursements.

Uveitis Treatment Market Trends:

Increasing Prevalence of Autoimmune Diseases

The uveitis treatment demand is stimulated by the increased rate of autoimmune diseases all over the world. As reported by the National Institutes of Health (NIH), autoimmune diseases are estimated to affect 23.5 million Americans, who have rheumatoid arthritis, inflammatory bowel disease, and lupus among other diseases develop uveitis as a sequel. It is important to note that this prevalence proves the high requirement for efficient uveitis therapies targeted at autoimmune diseases and stimulating the demand in the market. Thus, as these diseases move high across the world, treatment aims for uveitis and its therapies controlling the symptoms and it addresses the autoimmune processes that cause the disease to achieve better results in patients' lives.

Advancements in Biologics and Immunotherapy Therapies

Biologics and immunomodulatory therapies have revolutionized uveitis management by modulation of immune-mediated processes. The National Institutes of Health (NIH) has approved various biologics for autoimmune diseases, such as uveitis, signifying the change towards the use of cost-effective and effective biologics. Such therapies have benefits such as lower probability of side effects affecting other organs in the body than other treatments like corticosteroids which in turn is witnessing patients being more compliant to the treatment regimens that are recommended to them. As a result, there are continued markets in biotechnology and immunology leading to product development in biologics and immunomodulators extending the opportunities for the treatment of uveitis in the global market.

Rising Healthcare Expenditure and Research Funding

Increased government spending in healthcare systems, development strategies, and advances in healthcare are fueling the uveitis treatment market value. In the USA, the NIH supports significant funding to investigate uveitis and other auto-immune disorders, and this research has been a multisectoral and multiparty cooperation among universities, pharmaceutical industries, and hospitals. This financial support further brings a positive change to the progression of new treatments for uveitis as it pushes the development of new drugs, biologics, and treatment methods. Moreover, research grants and clinical trials that are supported by the government offer essential frameworks and resources to support the exploration of novel therapeutic profiles and verify the effectiveness of treatments. These dynamics make the uveitis treatment market highly research-intensive, as it capitalizes on the conversion of discoveries into clinically useful products and services that address existing requirements and enhance patient experience worldwide.

Uveitis Treatment Market Segmentation:

Breakup by Treatment Type:

  • Corticosteroids
  • Immunosuppressant
  • Monoclonal Antibodies
  • Cycloplegic Agents
  • Antibiotics
  • Antivirals
  • Antifungal
  • Analgesics

Corticosteroids account for the majority of the market share

As per the uveitis treatment market forecast, Corticosteroids thus dominate the uveitis treatment market by share since they help reduce inflammation and maintain vision in affected individuals. The National Institutes of Health (NIH) reported that corticosteroids are the primary therapy for uveitis, as they yield fast control of inflammation and signs about different uveitis types, anterior, posterior, and panuveitis. The main indications for these medicines are to lessen the body's ability to fight infection in the eye and diminish inflammation, which provides fast and effective relief and enhances the degree of patient's health. Corticosteroids can be administered through eye drops, injections, and oral tablets depending on the intensity of the situation and condition of the patient. As corticosteroids present possible side-effects, including rising intraocular pressure and postoperative cataract formation by long-term application, they remain preferred to other competitors while moderately effective topical NSAIDs are not as popular in uveitis treatment despite frequent use in ophthalmological practice.

Breakup by Disease Type:

  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis

Anterior uveitis holds the largest share of the industry

Anterior uveitis holds a leading position in the segmentation of uveitis treatment because of its greater incidence and the necessity of unique therapy. The National Institutes of Health (NIH) categorizes anterior uveitis as the most prevalent type of uveitis which accounts for 50-60% of all uveitis reported in the United States. This is caused by inflammation of the structures of the anterior part of the eye known as the uvea, it is linked with autoimmune diseases, infections, or physical injury. As a result, the pattern implies the treatment of anterior uveitis requires different management strategies such as topical corticosteroids and pupil-dilating agents available, routinely managed in clinics or ophthalmology and retail outlets, thus creating a favorable

Breakup by Cause:

  • Infectious
  • Non-infectious

Non-infectious represents the leading market segment

Non-infectious drive the uveitis treatment market revenue as the condition is more frequent than the infection-related kind and was addressed using improving evidence-based individualized treatment targeting autoimmune and inflammation processes. According to the National Institutes of Health (NIH), non-infectious uveitis accounts for approximately 80-90% of all uveitis cases in the United States. This form of uveitis is more related to autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, lupus, and the need for biologics and immunomodulatory agents. It has been observed by researchers from across the world that the cases of autoimmune diseases are continuously increasing, which strengthens the market position of the non-infectious forms of uveitis treatments. The modern pharmaceutical industry concentrates on the development of proper individual antiretirologic preparations to target more effectively the immunopathogenetic background of non-infectious uveitis with minimal side effects from systemic administration, thus creating a favorable uveitis treatment market outlook.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Retail pharmacies exhibit a clear dominance in the market

Retail pharmacies hold the largest market share of uveitis treatment primarily because they are easily accessible, and convenient, especially to the patients and they also engage in the dispensing of drugs. The National Community Pharmacists Association (NCPA) repoted that retail pharmacies in the United States dispense about 72% of prescriptions emphasizing the centrality of pharmacists in dispensing of medication. This uveitis treatment market overview shows that patients diagnosed with uveitis can conveniently get prescribed medicines such as corticosteroid, immunosuppressant, and biologic agents from the retail pharmacy at a faster pace. Additionally, retail pharmacies involve patient counseling, medication and health insurance information and management, which improves patient satisfaction and outcomes. Stakeholders use them to interface with the health systems and electronic health records, thereby providing continuity of care to patients with uveitis. Due to increased diversification of services and sophisticated patient and consumer focus in retail pharmacy, they significantly contribute to meeting the increasing needs of the market for uveitis medications and dominating the distribution of drugs.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest uveitis treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil Mexico, and others) and the Middle East and Africa. According to the report, North America was the largest regional market for uveitis treatment.

As per the uveitis treatment market report, North America holds the largest market share due to its well-developed and advanced healthcare sector, acceptance of novel therapeutic management, and direct spending on research and development. As reported by the National Institutes of Health (NIH), a significant budget is devoted to autoimmune disease studies in the United States alone and there exists a conducive environment for numerous clinical trials and partnerships among various pharmaceutical entities, research institutions, and caregivers. Such strategic investment allows North American countries to take a frontline in the development and commercialization of biologics, immunomodulatory, and other approaches to treating uveitis. Also, presenting a higher frequency of autoimmune diseases which later develop into uveitis, the North American region needs efficient uveitis treatment and management, thereby carrying the market leadership of the global uveitis market.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the uveitis treatment industry include AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., and Santen Pharmaceutical Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The uveitis treatment companies are focusing on the development of uveitis treatment include pharmaceutical companies and research institutions to meet the various challenges presented by the uveitis disease process through clinical trials. The market leaders such as AbbVie, Novartis, and Allergan are committed to research and development to launch new drugs that address specific immunological processes of uveitis development. For instance, the research strategies of AbbVie involve recent collaborations and clinical trials that explore the usage of biologics for autoimmune uveitis, proving the focus on precision medicine. Many of these activities are funded through government and research grants that promote academic-industry collaboration to advance therapeutic progress and improve patients' care in the context of the shifting uveitis treatment paradigm, thus fueling uveitis treatment industry growth.

Key Questions Answered in This Report

  • 1.What was the size of the global uveitis treatment market in 2024?
  • 2.What is the expected growth rate of the global uveitis treatment market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global uveitis treatment market?
  • 4.What are the key factors driving the global uveitis treatment market?
  • 5.What is the breakup of the global uveitis treatment market based on the treatment type?
  • 6.What is the breakup of the global uveitis treatment market based on the disease type?
  • 7.What is the breakup of the global uveitis treatment market based on the cause?
  • 8.What is the breakup of the global uveitis treatment market based on the distribution channel?
  • 9.What are the key regions in the global uveitis treatment market?
  • 10.Who are the key players/companies in the global uveitis treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Uveitis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunosuppressant
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Monoclonal Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cycloplegic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Antivirals
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Antifungal
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Analgesics
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Anterior Uveitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Posterior Uveitis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intermediate Uveitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panuveitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Cause

  • 8.1 Infectious
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-infectious
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alimera Sciences Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Bausch & Lomb Incorporated (Bausch Health)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 Enzo Biochem Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Eyegate Pharmaceuticals Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Eyepoint pharmaceuticals Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Regeneron Pharmaceuticals Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Santen Pharmaceutical Co. Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Uveitis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Uveitis Treatment Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Uveitis Treatment Market: Breakup by Treatment Type (in %), 2024
  • Figure 4: Global: Uveitis Treatment Market: Breakup by Disease Type (in %), 2024
  • Figure 5: Global: Uveitis Treatment Market: Breakup by Cause (in %), 2024
  • Figure 6: Global: Uveitis Treatment Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Uveitis Treatment Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Uveitis Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Uveitis Treatment (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Uveitis Treatment (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Uveitis Treatment (Immunosuppressant) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Uveitis Treatment (Immunosuppressant) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Uveitis Treatment (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Uveitis Treatment (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Uveitis Treatment (Cycloplegic Agents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Uveitis Treatment (Cycloplegic Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Uveitis Treatment (Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Uveitis Treatment (Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Uveitis Treatment (Antivirals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Uveitis Treatment (Antivirals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Uveitis Treatment (Antifungal) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Uveitis Treatment (Antifungal) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Uveitis Treatment (Analgesics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Uveitis Treatment (Analgesics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Uveitis Treatment (Anterior Uveitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Uveitis Treatment (Anterior Uveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Uveitis Treatment (Posterior Uveitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Uveitis Treatment (Posterior Uveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Uveitis Treatment (Intermediate Uveitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Uveitis Treatment (Intermediate Uveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Uveitis Treatment (Panuveitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Uveitis Treatment (Panuveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Uveitis Treatment (Infectious) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Uveitis Treatment (Infectious) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Uveitis Treatment (Non-infectious) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Uveitis Treatment (Non-infectious) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Uveitis Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Uveitis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Uveitis Treatment (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Uveitis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Uveitis Treatment (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Uveitis Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Uveitis Treatment (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Uveitis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: North America: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: North America: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: United States: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: United States: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Canada: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Canada: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Asia Pacific: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Asia Pacific: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: China: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: China: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Japan: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Japan: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: India: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: India: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: South Korea: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: South Korea: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Australia: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Australia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Indonesia: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Indonesia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Europe: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Europe: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Germany: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Germany: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: France: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: France: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: United Kingdom: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: United Kingdom: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Italy: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Italy: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Spain: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Spain: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Russia: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Russia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Latin America: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Latin America: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Brazil: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Brazil: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Mexico: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Mexico: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Middle East and Africa: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Middle East and Africa: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Global: Uveitis Treatment Industry: SWOT Analysis
  • Figure 94: Global: Uveitis Treatment Industry: Value Chain Analysis
  • Figure 95: Global: Uveitis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Uveitis Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Uveitis Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 3: Global: Uveitis Treatment Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 4: Global: Uveitis Treatment Market Forecast: Breakup by Cause (in Million USD), 2025-2033
  • Table 5: Global: Uveitis Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Uveitis Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Uveitis Treatment Market Structure
  • Table 8: Global: Uveitis Treatment Market: Key Players